ACTRN12620000470998撤回1 期
Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.
Firebrick Pharma Pty Ltd0 个研究点目标入组 20 人开始时间: 2020年4月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Adult (18+ years old) patients with
- •(a) confirmed COVID-19 symptoms and
- •(b) symptom onset within the past five days.
排除标准
- •Known iodine sensitivity
- •Previously diagnosed thyroid disease
- •Previously diagnosed kidney disease
- •Known to be pregnant or currently breastfeeding
研究者
相似试验
已完成
1 期
Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people in South Africa with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.COVID-19 PositiveInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12621000034831Firebrick Pharma Limited23
进行中（未招募）
不适用
A pilot study of the ability of povidone-iodine (PVP-I) 0.5% aqueous solution oral/nasal spray and mouthwash to kill the SARS-CoV-2 virus in people with COVID-19ISRCTN13447477Royal Surrey County Hospital NHS Foundation Trust22
已完成
3 期
Confirmatory Phase III study of Nasodine Nasal Spray (povidone-iodine 0.5%) as a symptomatic treatment for early stage common cold in the natural setting.Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesCommon ColdACTRN12621000604808Firebrick Pharma Limited502
进行中（未招募）
1 期
A Phase IIb pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance - VIKINGHIV-1 infected antiretroviral therapy experienced adults with raltegravir resistanceMedDRA version: 9.1 Level: LLT Classification code 10008922 Term: Chronic infection with HIVEUCTR2009-010270-37-FRGlaxoSmithKline Research and Development Ltd51
进行中（未招募）
不适用
A Phase IIb pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance - VIKINGHIV-1-infected adult subjects with raltegravir resistance.MedDRA version: 12.0Level: LLTClassification code 10008922Term: Chronic infection with HIVEUCTR2009-010270-37-ITGlaxoSmithKline Research and Development Ltd30